Cargando…

COVID-19 outbreak and acute cholecystitis in a Hub Hospital in Milan: wider indications for percutaneous cholecystostomy

BACKGROUND: COVID-19 pandemic has impacted the Italian National Health Care system at many different levels, causing a complete reorganization of surgical wards. In this context, our study retrospectively analysed the management strategy for patients with acute cholecystitis. METHODS: We analysed al...

Descripción completa

Detalles Bibliográficos
Autores principales: Barabino, Matteo, Piccolo, Gaetano, Trizzino, Arianna, Fedele, Veronica, Ferrari, Carlo, Nicastro, Vincenzo, Pisani Ceretti, Andrea, De Nicola, Enrico, Mariani, Nicolò Maria, Giovenzana, Marco, Scifo, Giovanna, Mazza, Massimiliano, Vercelli, Ruggero, Santambrogio, Roberto, Luigiano, Carmelo, Opocher, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022294/
https://www.ncbi.nlm.nih.gov/pubmed/33823831
http://dx.doi.org/10.1186/s12893-021-01137-y
_version_ 1783674903907532800
author Barabino, Matteo
Piccolo, Gaetano
Trizzino, Arianna
Fedele, Veronica
Ferrari, Carlo
Nicastro, Vincenzo
Pisani Ceretti, Andrea
De Nicola, Enrico
Mariani, Nicolò Maria
Giovenzana, Marco
Scifo, Giovanna
Mazza, Massimiliano
Vercelli, Ruggero
Santambrogio, Roberto
Luigiano, Carmelo
Opocher, Enrico
author_facet Barabino, Matteo
Piccolo, Gaetano
Trizzino, Arianna
Fedele, Veronica
Ferrari, Carlo
Nicastro, Vincenzo
Pisani Ceretti, Andrea
De Nicola, Enrico
Mariani, Nicolò Maria
Giovenzana, Marco
Scifo, Giovanna
Mazza, Massimiliano
Vercelli, Ruggero
Santambrogio, Roberto
Luigiano, Carmelo
Opocher, Enrico
author_sort Barabino, Matteo
collection PubMed
description BACKGROUND: COVID-19 pandemic has impacted the Italian National Health Care system at many different levels, causing a complete reorganization of surgical wards. In this context, our study retrospectively analysed the management strategy for patients with acute cholecystitis. METHODS: We analysed all patients admitted to our Emergency Department for acute cholecystitis between February and April 2020 and we graded each case according to 2018 Tokyo Guidelines. All patients were tested for positivity to SARS-CoV-2 and received an initial conservative treatment. We focused on patients submitted to cholecystostomy during the acute phase of pandemic and their subsequent disease evolution. RESULTS: Thirty-seven patients were admitted for acute cholecystitis (13 grade I, 16 grade II, 8 grade III). According to Tokyo Guidelines (2018), patients were successfully treated with antibiotic only, bedside percutaneous transhepatic gallbladder drainage (PC) and laparoscopic cholecystectomy (LC) in 29.7%, 21.6% and 48.7% of cases respectively. Therapeutic strategy of three out of 8 cases, otherwise fit for surgery, submitted to bedside percutaneous transhepatic gallbladder drainage (37.5%), were directly modified by COVID-19 pandemic: one due to the SARS-CoV-2 positivity, while two others due to unavailability of operating room and intensive care unit for post-operative monitoring respectively. Overall success rate of percutaneous cholecystostomy was of 87.5%. The mean post-procedural hospitalization length was 9 days, and no related adverse events were observed apart from transient parietal bleeding, conservatively treated. Once discharged, two patients required readmission because of acute biliary symptoms. Median time of drainage removal was 43 days and only 50% patients thereafter underwent cholecystectomy. CONCLUSIONS: Percutaneous cholecystostomy has shown to be an effective and safe treatment thus acquiring an increased relevance in the first phase of the pandemic. Nowadays, considering we are forced to live with the SARS-CoV-2 virus, PC should be considered as a virtuous, alternative tool for potentially all COVID-19 positive patients and selectively for negative cases unresponsive to conservative therapy and unfit for surgery.
format Online
Article
Text
id pubmed-8022294
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80222942021-04-06 COVID-19 outbreak and acute cholecystitis in a Hub Hospital in Milan: wider indications for percutaneous cholecystostomy Barabino, Matteo Piccolo, Gaetano Trizzino, Arianna Fedele, Veronica Ferrari, Carlo Nicastro, Vincenzo Pisani Ceretti, Andrea De Nicola, Enrico Mariani, Nicolò Maria Giovenzana, Marco Scifo, Giovanna Mazza, Massimiliano Vercelli, Ruggero Santambrogio, Roberto Luigiano, Carmelo Opocher, Enrico BMC Surg Research Article BACKGROUND: COVID-19 pandemic has impacted the Italian National Health Care system at many different levels, causing a complete reorganization of surgical wards. In this context, our study retrospectively analysed the management strategy for patients with acute cholecystitis. METHODS: We analysed all patients admitted to our Emergency Department for acute cholecystitis between February and April 2020 and we graded each case according to 2018 Tokyo Guidelines. All patients were tested for positivity to SARS-CoV-2 and received an initial conservative treatment. We focused on patients submitted to cholecystostomy during the acute phase of pandemic and their subsequent disease evolution. RESULTS: Thirty-seven patients were admitted for acute cholecystitis (13 grade I, 16 grade II, 8 grade III). According to Tokyo Guidelines (2018), patients were successfully treated with antibiotic only, bedside percutaneous transhepatic gallbladder drainage (PC) and laparoscopic cholecystectomy (LC) in 29.7%, 21.6% and 48.7% of cases respectively. Therapeutic strategy of three out of 8 cases, otherwise fit for surgery, submitted to bedside percutaneous transhepatic gallbladder drainage (37.5%), were directly modified by COVID-19 pandemic: one due to the SARS-CoV-2 positivity, while two others due to unavailability of operating room and intensive care unit for post-operative monitoring respectively. Overall success rate of percutaneous cholecystostomy was of 87.5%. The mean post-procedural hospitalization length was 9 days, and no related adverse events were observed apart from transient parietal bleeding, conservatively treated. Once discharged, two patients required readmission because of acute biliary symptoms. Median time of drainage removal was 43 days and only 50% patients thereafter underwent cholecystectomy. CONCLUSIONS: Percutaneous cholecystostomy has shown to be an effective and safe treatment thus acquiring an increased relevance in the first phase of the pandemic. Nowadays, considering we are forced to live with the SARS-CoV-2 virus, PC should be considered as a virtuous, alternative tool for potentially all COVID-19 positive patients and selectively for negative cases unresponsive to conservative therapy and unfit for surgery. BioMed Central 2021-04-06 /pmc/articles/PMC8022294/ /pubmed/33823831 http://dx.doi.org/10.1186/s12893-021-01137-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Barabino, Matteo
Piccolo, Gaetano
Trizzino, Arianna
Fedele, Veronica
Ferrari, Carlo
Nicastro, Vincenzo
Pisani Ceretti, Andrea
De Nicola, Enrico
Mariani, Nicolò Maria
Giovenzana, Marco
Scifo, Giovanna
Mazza, Massimiliano
Vercelli, Ruggero
Santambrogio, Roberto
Luigiano, Carmelo
Opocher, Enrico
COVID-19 outbreak and acute cholecystitis in a Hub Hospital in Milan: wider indications for percutaneous cholecystostomy
title COVID-19 outbreak and acute cholecystitis in a Hub Hospital in Milan: wider indications for percutaneous cholecystostomy
title_full COVID-19 outbreak and acute cholecystitis in a Hub Hospital in Milan: wider indications for percutaneous cholecystostomy
title_fullStr COVID-19 outbreak and acute cholecystitis in a Hub Hospital in Milan: wider indications for percutaneous cholecystostomy
title_full_unstemmed COVID-19 outbreak and acute cholecystitis in a Hub Hospital in Milan: wider indications for percutaneous cholecystostomy
title_short COVID-19 outbreak and acute cholecystitis in a Hub Hospital in Milan: wider indications for percutaneous cholecystostomy
title_sort covid-19 outbreak and acute cholecystitis in a hub hospital in milan: wider indications for percutaneous cholecystostomy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022294/
https://www.ncbi.nlm.nih.gov/pubmed/33823831
http://dx.doi.org/10.1186/s12893-021-01137-y
work_keys_str_mv AT barabinomatteo covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT piccologaetano covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT trizzinoarianna covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT fedeleveronica covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT ferraricarlo covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT nicastrovincenzo covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT pisanicerettiandrea covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT denicolaenrico covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT marianinicolomaria covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT giovenzanamarco covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT scifogiovanna covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT mazzamassimiliano covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT vercelliruggero covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT santambrogioroberto covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT luigianocarmelo covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy
AT opocherenrico covid19outbreakandacutecholecystitisinahubhospitalinmilanwiderindicationsforpercutaneouscholecystostomy